A-SKIN Nederland BV
De Boelelaan 1117
1081 HV Amsterdam
Website A-SKIN Nederland BV
E-mail A-SKIN Nederland BV
T +31 (0)20 444 26 24
F +31 (0)20 444 29 64

Employees in Amsterdam: 6
Employees in R&D: 3
Year of foundation: 2006

Company Profile

A-SKIN Nederland BV is a start-up from VUmc Amsterdam, and is positioned as a tissue engineering service company developing and commercialising autologous skin products from her GMP skin culture laboratory. Current customers are located in hospitals, out-patient clinics and (long term) care facilities in the Netherlands. In the coming years the patented A-SKIN autologous skin culture technique and related products will be made available trough out-licensing and daughter companies in other European countries and beyond.
With Tiscover® A-SKIN Nederland BV offers patients and professionals a novel and superior product for healing chronic, inert skin wounds. This product fills an unmet medical need in the treatment of various skin ulcers such as due to decubitus, diabetes or vascular malfunctioning.

Science and Technologies or Services

Alliances

• VU medical centre, Amsterdam
• Euro Skin Bank, Beverwijk
• Brandwonden centrum, Beverwijk

Keywords

• Tissue culturing
• Biomaterials
• Skin wounds
• Chronic leg ulcers
• Venous leg ulcers
• Decubitus ulcers
• Diabetic ulcers
  
  

Academic Medical Center (AMC)
Meibergdreef 9
1105 AZ Amsterdam
Website Academic Medical Center
E-mail Amsterdam Medical Center
T +31 (0)20 566 50 56
F +31 (0)20 566 91 68

Employees in Amsterdam: 6,500
Employees in R&D: 1,400
Year of foundation: 1983

Company Profile

Science and Technologies or Services

AMC is active in the following research fields:

• Cardiovascular Diseases
• Gastr-intestinal diseases
• Immunity and Infections
• Metabolic Disorders
• Neurologic and Psychiatric Disorders
• Oncology
• Public Health and Epidemiology

AMC also offers advanced facilities and highly qualified personnel in the areas of gene and cell therapies, viral vector production, genomics, proteomics, metabolomics, bioinformatics, imaging, and animal models.

Alliances

AMC spin-offs:

• AIMM Therapeutics
• AMCAS
• Amsterdam Molecular Therapeutics (AMT)
• Arthrogen
• Hep-Art Medical Devices
• IATEC
• Macrozyme
• MicroVision Medical
• Primagen
• Valletta Health

Keywords

• Academic hospital
• Medical research
• License opportunities
• Spin-off companies
  

ACE Pharmaceuticals B.V. Schepenveld 41 3891 ZK Zeewolde Website ACE Pharmaceuticals B.V. E-mail ACE Pharmaceuticals B.V. T +31 (0)36 522 72 01 F +31 (0)36 522 90 96 Employees in Amsterdam: 34 Employees in R&D: Year of foundation: 1990

Advanced Interim Management Prinses Beatrixlaan 266b 2273 XV Voorburg Website Advanced Interim Management E-mail Advanced Interim Management T +31 (0)70 211 52 62 F +31 (0)70 211 52 62 Employees in Amsterdam: 0 Employees in R&D: 0 Year of foundation: 2009

Company profile

Advanced Interim Management is an innovative organisation with extensive Supply Chain expertise.
We offer a concept of professionals for professionals. Our Supply Chain experts have gained international experience at operational and/or strategic level at companies such as Astellas, Mead Johnson, Genzyme, Amgen, MSD, DSM, GE, Hexion, Lyondell, Bausch & Lomb, Centocor, BMS, PWC, KPMG.

Science and Technologies or Services

Advanced Interim Management is completely focussed on the total value Chain, always starting with the demands of the final customer. Combining Supply Chain expertise within the Pharmaceutical, Life Science, Biotech and Chemical Industry and Finance/Fiscal and IT expertise, are key to deliver the required service levels and expected solutions. We believe in securing results and execution/implementation of proposed improvements.

Alliances

Advanced Interim Management works closely together with Biofarmind, the Dutch association for the Bio-Pharmaceutical Industry. Knowledge ex-change on Supply Chain issues within the Bio-Pharmaceutical Industry.
Advanced Interim Management cooperates with Integron, specialists in performance measurement.

Keywords

• Biotech;
• Pharmaceutical;
• Life Science;
• Chemical;
• Supply Chain;
• Interim;
• Consultancy.

Aescap Venture
Strawinskylaan 1525
1077 XX Amsterdam
Website
e-mail
T +31 (0)20 570 29 40
F +31 (0)20 673 78 46

Employees in Amsterdam: 11
Employees in R&D: 0
Year of foundation: 2006

Company Profile

Aescap Venture is a venture capital company investing in private medical companies in Europe. Aescap Venture has a long-term investment horizon and invests in high-potential companies. This involves investments in all phases of development with an emphasis on earlier stages. Aescap Venture’s added value is based on a multi-disciplinary team of experienced investment partners with proven track records of success and the skills to coach entrepreneurs in accelerating the growth of their companies.

Science and Technologies or Services

At Aescap Venture, people are our greatest asset. Our partners have extensive experience and proven performance to help create successful businesses. As a result of our focus and dedication in the medical market we fully understand the opportunities and threats within this challenging arena.

Keywords

• Venture Capital
• Medical companies
• Life sciences
• Hands-on approach

Agendia B.V.
Science Park 406
1098 XH Amsterdam
Website Agendia B.V. 
E-mail Agendia B.V.
Promotion video Agendia
T +31 (0)20 462 15 00
F +31 (0)20 462 15 05

Employees in Amsterdam: 65
Employees in R&D: 9
Year of foundation: 2003

Company Profile

Agendia is committed to improving the quality of life of people suffering from cancer. The company is a world leader in gene expression analysis-based diagnostics and has developed a series of validated, state of the art tests using tumor gene expression profiling. The tests help oncologists make the right decision regarding the treatment of the individual cancer patient. Agendia was the first company to commercialise a prognostic test, MammaPrint, which predicts the risk of breast cancer recurrence. MammaPrint was cleared by the US Food and Drugs administration in February 2007.
Agendia was founded in 2003 by Netherlands Cancer Institute (NKI) researchers Laura van 't Veer, René Bernards and Bernhard Sixt and is located in Amsterdam in the Netherlands. Agendia is now in the market with three products: MammaPrint, CupPrint and DiscoverPrint.

Science and Technologies or Services

Agendia has developed high-quality diagnostic methods using microarray gene expression profiling to determine tumor specific properties. Our in vitro diagnostic laboratory services offered to physicians and pharmaceutical companies improve the accuracy of metastasis risk prediction, disease origin, targeted drug development or pre-selection of patients eligible for clinical trials.

Alliances

• Netherlands Cancer Institute

Keywords

• Gene expression analysis
• Genomic profiling
• Microarray
• Cancer
• Diagnostic
• MammaPrint
• CupPrint
• DiscoverPrint
  
  

AIMM Therapeutics B.V.
Meibergdreef 45
1105 BA Amsterdam
Website AIMM Therapeutics B.V.
E-mail AIMM Terapeutics B.V.
T +31 (0)20 566 26 48
F +31 (0)20 566 91 58

Employees in Amsterdam: 5
Employees in R&D: 5
Year of foundation: 2005

Company Profile

AIMM’s portfolio is based on proprietary platform technologies for directed, fast and efficient development of fully human monoclonal antibodies. Many innovative products for a wide range of viral and bacterial diseases as well as for cancer, are being developed.

Science and Technologies or Services

The goal is to isolate antibody-producing B cells from humans that have resolved a pathogenic challenge with high or exceptional efficiency. This would allow for the direct isolation of monoclonal antibodies with proven effectiveness in a clinical setting. Such proprietary B cell immortalization technologies for the selective isolation of human B cells shall lead to antibodies with desirable specificities.

Alliances

• AMC-Amsterdam;
• UMCU-Utrecht;
• NVI-Bilthoven.

Keywords

• Human antibodies;
• Vaccines.

Alliance Healthcare Koningsbeltweg 52 1329 AK Almere Website Alliance Healthcare E-mail Alliance Healthcare T +31 (0)36 539 74 11 F +31 (0)36 539 74 34 Employees in Amsterdam: Employees in R&D: Year of foundation:

AM-Pharma B.V.
Rumpsterweg 6
3981 AK Bunnik
Website AM-Pharma B.V.
E-mail AM-pharma B.V.
T +31 (0)30 228 92 22
F +31 (0)30 228 92 20

Employees in Amsterdam: 17
Employees in R&D: 17
Year of foundation: 2000

Company Profile

AM-Pharma is a biopharmaceutical company, based in Bunnik, The Netherlands. The company is focused on the pre-clinical and clinical development of novel therapeutics to treat inflammatory diseases and infectious diseases. All our products address high medical needs and commercially attractive markets.
Our products are based on endogenous proteins and (protein derived) peptides, optimised to fight inflammatory diseases and infections. AM-Pharma has intellectual property around two scientific platforms:

• Enhancing Toll Like Receptor mediated activation of innate immune cells
• Dephosphorylation of extracellular substrates to influence disease processes

So far, AM-Pharma has developed two products originating from its intellectual property franchise, Alkaline Phosphatase and hLF1-11 up to the point of initial proof of clinical efficacy and safety.
AM-Pharma currently employs 17 people. We out-source all non-core know how dependent development work to specialist third party organisations.
Once our products have shown to be safe and effective in patients we out-license our products to collaboration partners who become responsible for further development and worldwide marketing.

Science and Technologies or Services

Alkaline Phosphatase (AP) (acute renal failure and ulcerative colitis)
The endogenous enzyme alkaline phosphatase is expressed in various tissues throughout the human body including kidney and GI tract. AP has been shown to dephosphorylate LPS to a non-toxic form that acts as a partial antagonist on the LPS receptor complex. In addition to LPS, AP can dephosphorylate different other substrates e.g. ATP and through this dephosphorylation interfere with inflammatory response and associated tissue damage. Proof of concept has been shown in Phase IIa Proof Of Concept trials in Acute Renal Failure and Ulcerative Colitis.

HLF 1-11 Anti microbial peptide
The antimicrobial peptide hLF1-11 comprises the first 11 N-terminal amino acids of the endogenous protein; human lactoferrin. The compound exerts both antibacterial and antifungal activity against a broad range of microorganisms. Moreover, it appears that hLF1-11 has a low propensity to generate resistance in microorganisms, because it acts by stimulating the innate immune system. Phase IIa Proof Of Concept trials have are in preparation in MRSA infections and systemic Candida infections.

Keywords

• Acute Renal Failure
• Ulcerative Colitis
• MRSA
• Systemic candida infection
• Phase II clinical development
• Anti-infective
• Anti-inflammatory
  

AMC Medical Business Park
Meibergdreef 5
1105 AZ Amsterdam
Website AMC Medical Business Park
E-mail AMC Medical Business Park
T +31 (0)20 566 41 36
F +31 (0)20 566 91 59

Employees in Amsterdam: 2
Employees in R&D:
Year of foundation:

Company Profile

The Medical Business Park (MBP) is currently under development at the site of the Academic Medical Center Amsterdam (AMC). The MBP is intended for companies which wish to develop products and services in the area of (bio)medical sciences together with, or with the support of, the AMC. It is the place where they draw their future. The AMC places a high value on the exchange and broadening of knowledge, and also wishes to make better use of knowledge from its own research. AMC’s technology transfer office, Bureau Kennis Transfer (BKT), plays an essential role here. BKT facilitates patenting, partnering, due diligence and control in relation to all (commercial) management aspects of research findings, technology transfer and the foundation of spin-off companies.

The AMC offers these companies a broad package of facilities and support, including access to patients for research and R&D collaborations with scientifically well-known groups and, through BKT, a professional office which efficiently handles e.g. patent- or R&D contract related matters. A setting and synergy of this kind means exploring and developing new areas becomes possible.

The AMC traditionally has strong roots in a number of wide-ranging research areas: infectious diseases and immunology, metabolic disorders, cardiovascular disorders, stomach, intestinal and liver disorders, neurological and psychiatric disorders, public health, and to an increasing extent also in oncology.

Science and Technologies or Services

One of the major services of the MBP Development Office will be the support of companies regarding business development, networking and supply facilities as e.g. accountancy, patenting, partnering, due diligence and control in relation to all (commercial) management aspects of research findings, technology transfer and the foundation of spin-off companies.

Alliances

• AMC
• Gemeente Amsterdam

Keywords

• Biopharmaceuticals
• Medical devices
• Patient care systems
• Infectious diseases
• Immunology
• Metabolic disorders
• Cardiovascular disorders
• Stomach, intestinal and liver disorders
• Neurological and psychiatric disorders
• Public health
• Oncology
• Science park